Consensus diagnosis and therapy of soft tissue sarcoma

被引:10
作者
Brodowicz, Thomas [1 ]
Amann, Gabriele [2 ]
Leithner, Andreas [3 ]
Sztankay, Arpad [4 ]
Kainberger, Franz [5 ]
Eisterer, Wolfgang [6 ]
Liegl-Atzwanger, Bernadette [7 ]
Rachbauer, Franz [8 ]
Rath, Thomas [9 ]
Bergmann, Michael [10 ]
Funovics, Philipp T. [12 ]
Ploner, Ferdinand [11 ]
Windhager, Reinhard [12 ]
机构
[1] Univ Klin Innere Med, Klin Abt Onkol, Vienna, Austria
[2] Med Univ Wien, Klin Inst Pathol, Vienna, Austria
[3] Univ Klin Orthopadie & Orthopad Chirurg, Graz, Austria
[4] Med Univ Innsbruck, Univ Klin Shrahlentherapie Radioonkol, Innsbruck, Austria
[5] Univ Klin Radiodiagnost, Abt Neuro & Muskuloskeletale Radiol, Vienna, Austria
[6] Univ Klin Innere Med I, Innsbruck, Austria
[7] Med Univ Graz, Inst Pathol, Graz, Austria
[8] Univ Klin Orthopadie, Innsbruck, Austria
[9] Univ Klin Chirurg, Klin Abt Wiederherstellungs & Plast Chirurg, Vienna, Austria
[10] Med Univ Wien, Abt Allgemeinchirurg, Vienna, Austria
[11] Univ Klin Innere Med, Klin Abt Onkol, Graz, Austria
[12] Univ Klin Orthopadie, Vienna, Austria
关键词
Soft tissue sarcoma; consensus; Austria; multimodality treatment; guidelines; RANDOMIZED PHASE-II; RADIATION-THERAPY; EUROPEAN-ORGANIZATION; PROGNOSTIC-FACTORS; NEOADJUVANT CHEMOTHERAPY; HIGH-RISK; INTRAOPERATIVE BRACHYTHERAPY; POSTOPERATIVE RADIOTHERAPY; ADJUVANT CHEMOTHERAPY; BEAM RADIOTHERAPY;
D O I
10.1007/s00508-011-0079-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Soft tissue sarcomas are heterogeneous tumours and relatively uncommon. There have been advances over the past years concerning pathology, clinical behaviour, diagnosis strategies and the treatment. To summarize these advances as well as making it public is one of the goals of the following consensus guidelines. But why do we need special guidelines for Austria? There are international guidelines published by the European Society of Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN). The cause is that we need an explanation of the matrix the ESMO and the NCCN gave according to our clinical practice, the local requirements and facilities in Austria. The following recommendations were drawn up following a consensus meeting of sarcoma specialists from the three high volume centres located at the medical universities in Austria. All fields of involved physicians from diagnosis to therapy worked together to know that soft tissue sarcomas are an interdisciplinary challenge and multimodal treatment is essential. For this reason, these guidelines not only explain but also give the state of the art and clear recommendations. One of the most important guidelines is that any patient with a suspected soft tissue sarcoma should be referred to one of the three university centres and managed by a specialist sarcoma multidisciplinary team. We hope that the consensus is helpful for the clinical practice and improves the quality of care for patients with soft tissue sarcomas in Austria.
引用
收藏
页码:85 / 99
页数:15
相关论文
共 50 条
  • [31] Extremity Soft Tissue Sarcoma: Role of Local Control
    Brinkmann, Elyse J.
    Ahmed, Safia K.
    Houdek, Matthew T.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (02)
  • [32] Conformal radiotherapy in management of soft tissue sarcoma in adults
    Le Pechoux, C.
    Llacer, C.
    Sargos, P.
    Moureau-Zabotto, L.
    Ducassou, A.
    Sunyach, M-P
    Biston, M-C
    Thariat, J.
    [J]. CANCER RADIOTHERAPIE, 2022, 26 (1-2): : 377 - 387
  • [33] Quality of life and patients' expectations in soft tissue sarcoma
    Jones, Robin L.
    Le Cesne, Axel
    [J]. FUTURE ONCOLOGY, 2018, 14 (10) : 51 - 62
  • [34] Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS)
    Garcia del Muro, Xavier
    de Alava, Enrique
    Artigas, Vicenc
    Bague, Silvia
    Brana, Alejandro
    Cubedo, Ricardo
    Cruz, Josefina
    Mulet-Margalef, Nuria
    Narvaez, Jose A.
    Martinez Tirado, Oscar
    Valverde, Claudia
    Verges, Ramona
    Vinals, Joan
    Martin-Broto, Javier
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (01) : 133 - 146
  • [35] Brazilian consensus on the diagnosis and treatment of extremities soft tissue sarcomas
    Spencer, Ranyell M. S. S. B.
    de Camargo, Veridiana P.
    Silva, Maria L. G.
    Pinto, Fabio F. E.
    Costa, Felipe D'Almeida
    Cequeira, Wagner S.
    Munhoz, Rodrigo R.
    Mello, Celso A.
    Schmerling, Rafael A.
    Filho, Waldec J. D.
    Coelho, Tharcisio M.
    Ambrosio, Alexandre V. A.
    Leite, Elton T. T.
    Hanna, Samir A.
    Nakagawa, Sueli A.
    Baptista, Andre M.
    Pinheiro, Rodrigo N.
    de Oliveira, Jadivan L.
    de Araujo, Marcelo Sa
    de Araujo, Raphael L. C.
    Laporte, Gustavo A.
    Quadros, Claudio de Almeida
    de Oliveira, Alexandre F.
    Lopes, Ademar
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2020, 121 (05) : 743 - 758
  • [36] New therapies in soft tissue sarcoma
    Vincenzi, Bruno
    Frezza, Anna Maria
    Santini, Daniele
    Tonini, Giuseppe
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2010, 15 (02) : 237 - 248
  • [37] Trimodality Treatment of Extremity Soft Tissue Sarcoma: Where Do We Go Now?
    Oberoi, Sapna
    Choy, Edwin
    Chen, Yen-Lin
    Scharschmidt, Thomas
    Weiss, Aaron R. R.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (04) : 300 - 326
  • [38] The role of neoadjuvant radiochemotherapy in the management of localized high-grade soft tissue sarcoma
    Kobus, Marta
    Roohani, Siyer
    Ehret, Felix
    Floercken, Anne
    Striefler, Jana Kaethe
    Brandes, Franziska
    Maerdian, Sven
    Rau, Daniel
    Wittenberg, Silvan
    Oellinger, Robert
    Kaul, David
    [J]. RADIATION ONCOLOGY, 2022, 17 (01)
  • [39] Pazopanib in the treatment of soft tissue sarcoma
    Schoeffski, Patrick
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (06) : 711 - 723
  • [40] The place of trabectedin in the treatment of soft tissue sarcoma: an umbrella review of the level one evidence
    Andreeva-Gateva, Pavlina
    Chakar, Shenol
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2019, 7 (03): : 105 - 115